We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of CTI BioPharma Corp. (“CTI” or the “Company”) (NASDAQ: CTIC) in connection with its acquisition by Swedish Orphan Biovitrum AB via tender offer.  Under the merger agreement, the Company’s shareholders will receive $9.10 cash for each share.  The transaction value is approximately $1.7 billion.

Weiss Law is investigating whether (i) CTI’s board acted in the best interests of Company shareholders in agreeing to the merger, (ii) the $9.10 merger consideration adequately compensates CTI’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.